Palovarotene hits a dead-end
24/01/20 -"As results of a futility analysis indicate that palovarotene’s phase III trial could miss the primary endpoint, Ipsen has suspended the studies associated with the drug. This is another blow after a ..."
Pages
53
Language
English
Published on
24/01/20
You may also be interested by these reports :
25/03/24
Perfect execution of capacity ramp-up key for meeting targets – TP increased to CHF 81 (from CHF 75) – Reduce reiterated
21/03/24
BioNTech reported weaker than expected FY23 sales figures (-17.7%), explained by the structure of the partnering deal with Pfizer. However, investors ...
20/03/24
FDA approves TRYVIO (aprocitentan) for hypertension
19/03/24
Family controlled UCB (ADD; Belgium) has been one of the strongest performing pharma stocks (+36% in the share price) in 2024. While the recent surge ...